International Journal of Thyroidology

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2466-1899   pISSN 2384-3799

Table. 1.

Table. 1.

Change of subjective symptoms, dose of antithyroid drug and thyroid function tests during the clinical course

First visit 4 weeks 8 weeks 12 weeks 16 weeks 17 weeks(admission) 19 weeks
TSH(0.25-4.0 mIU/L) 0.005 0.005 1.54 0.006 0.005 0.01 0.005
Free T4(0.78-1.94 ng/dL) 3.90 0.978 0.695 4.03 3.19 2.43 1.57
TRAb(0-1.5 IU/L) 3.6 3.4 4.86 17.7 19.8 18.9
Subjective symptoms
1) Typical* Severe Severe to moderate Mild Moderate Moderate Mild Mild
2) Atypical** Severe Severe Severe to moderate Severe Severe Severe Severe to moderate
Management MZ30 mg/day PTU200 mg/day PTU100 mg/day PTU200 mg/day MZ30 mg/day Anti-coagulation & plan RAI Tx → Sudden death

Typical* means typical symptoms of Graves disease (weight loss, heat intolerance, palpitation etc.).

Atypical** means atypical symptoms for Graves’ disease, but related to pulmonary embolism (calf pain, chest tightness, severe anxiety etc.).

MZ: methimazole, PTU: propylthiouracil, RAI: radioactive iodine, TRAb: TSH receptor antibody

Int J Thyroidol 2021;14:63-8 https://doi.org/10.11106/ijt.2021.14.1.63
© 2021 Int J Thyroidol